COMPASS Pathways plc (NASDAQ:CMPS)
| Market Cap | $1.14B+55.4% |
| Revenue (ttm) | $0 |
| Net Income | -$266.30M-12.2% |
| EPS | -$4.44-63.2% |
| Shares Out | 141.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,089,163 |
| Open | $8.32 |
| Previous Close | $8.65 |
| Day's Range | $7.82 - $8.43 |
| 52-Week Range | $4.88 - $15.87 |
| Beta | 2.41 |
| Analysts | Buy |
| Price Target | $20.17(+150.56%) |
| Earnings Date | Mar 23, 2027 |
About CMPS
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Analyst consensus
3 firms rating CMPS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 23, 2027Earnings report
$CMPS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CMPS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CMPS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CMPS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CMPS Revenue by Segment
| Single Operating Segment | $56.44M | 56.54% |
| Fair value change of warrant liabilities | $40.78M | 40.85% |
| Benefit from R&D tax credit | $2.05M | 2.05% |
| Other income | $556.00K | 0.56% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CMPS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CMPS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CMPS
| ARKGARK Genomic Revolution ETF | $48.56M |
| IBBiShares Biotechnology ETF | $7.09M |
| PSILAdvisorShares Psychedelics ETF | $3.98M |
| SBIOALPS Medical Breakthroughs ETF | $1.36M |
| TMSLT. Rowe Price Small-Mid Cap ETF | $1.25M |
| GWXState Street SPDR S&P International Small Cap ETF | $874.63K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CMPS’s recent data — informational, not investment advice
What’s Behind the Score
News check: FDA NDA submission for COMP360 and positive catalyst expectations for 2027 approval outweigh valuation opinion pieces.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| PSIL | AdvisorShares Psychedelics ETF | 10.56% |
| ARKG | ARK Genomic Revolution ETF | 2.64% |
| AADR | AdvisorShares Dorsey Wright | 1.44% |
| SURI | Simplify Propel Opportunities ETF | 1.09% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.83% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 0.73% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.57% |
| TDNA | T. Rowe Price Biotech ETF | 0.37% |
| ESIM | Eventide International ETF | 0.15% |
| GWX | State Street SPDR S&P International Small Cap ETF | 0.10% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.08% |
| IBB | iShares Biotechnology ETF | 0.07% |
Weight is the stock’s share of each fund’s holdings.
